NO20061322L - Kinazolinderivater som tyrosin kinase inhibitorer - Google Patents
Kinazolinderivater som tyrosin kinase inhibitorerInfo
- Publication number
- NO20061322L NO20061322L NO20061322A NO20061322A NO20061322L NO 20061322 L NO20061322 L NO 20061322L NO 20061322 A NO20061322 A NO 20061322A NO 20061322 A NO20061322 A NO 20061322A NO 20061322 L NO20061322 L NO 20061322L
- Authority
- NO
- Norway
- Prior art keywords
- quinazoline derivatives
- tyrosine kinase
- kinase inhibitors
- manufacture
- formula
- Prior art date
Links
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title abstract 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 102000001301 EGF receptor Human genes 0.000 abstract 1
- 108060006698 EGF receptor Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Structural Engineering (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0321620.7A GB0321620D0 (en) | 2003-09-16 | 2003-09-16 | Quinazoline derivatives |
GB0406163A GB0406163D0 (en) | 2004-03-19 | 2004-03-19 | Quinazoline derivatives |
PCT/GB2004/003923 WO2005026150A1 (en) | 2003-09-16 | 2004-09-13 | Quinazoline derivatives as tyrosine kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20061322L true NO20061322L (no) | 2006-06-15 |
Family
ID=34315440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20061322A NO20061322L (no) | 2003-09-16 | 2006-03-23 | Kinazolinderivater som tyrosin kinase inhibitorer |
Country Status (25)
Country | Link |
---|---|
US (2) | US7569577B2 (pt) |
EP (1) | EP1667991B1 (pt) |
JP (1) | JP4795952B2 (pt) |
AR (1) | AR045663A1 (pt) |
AT (1) | ATE395346T1 (pt) |
AU (1) | AU2004272348B2 (pt) |
BR (1) | BRPI0414489A8 (pt) |
CA (1) | CA2538884C (pt) |
CO (1) | CO5690594A2 (pt) |
CY (1) | CY1108186T1 (pt) |
DE (1) | DE602004013806D1 (pt) |
DK (1) | DK1667991T3 (pt) |
ES (1) | ES2305844T3 (pt) |
HK (1) | HK1091480A1 (pt) |
HR (1) | HRP20080329T3 (pt) |
IL (1) | IL174261A0 (pt) |
MX (1) | MXPA06002964A (pt) |
NO (1) | NO20061322L (pt) |
PL (1) | PL1667991T3 (pt) |
PT (1) | PT1667991E (pt) |
RU (1) | RU2378268C2 (pt) |
SI (1) | SI1667991T1 (pt) |
TW (1) | TW200519104A (pt) |
UA (1) | UA84167C2 (pt) |
WO (1) | WO2005026150A1 (pt) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003040108A1 (en) * | 2001-11-03 | 2003-05-15 | Astrazeneca Ab | Quinazoline derivatives as antitumor agents |
GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
GB0309009D0 (en) * | 2003-04-22 | 2003-05-28 | Astrazeneca Ab | Quinazoline derivatives |
GB0309850D0 (en) * | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
EP1667996B1 (en) * | 2003-09-16 | 2009-07-22 | Astrazeneca AB | Quinazoline derivatives |
GB0321648D0 (en) * | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
JP2007505873A (ja) * | 2003-09-16 | 2007-03-15 | アストラゼネカ アクチボラグ | チロシンキナーゼ阻害剤としてのキナゾリン誘導体 |
EP1664030A1 (en) * | 2003-09-16 | 2006-06-07 | AstraZeneca AB | Quinazoline derivatives |
GB0322409D0 (en) * | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
GB0326459D0 (en) * | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
US20080113874A1 (en) * | 2004-01-23 | 2008-05-15 | The Regents Of The University Of Colorado | Gefitinib sensitivity-related gene expression and products and methods related thereto |
WO2005070020A2 (en) * | 2004-01-23 | 2005-08-04 | The Regents Of The University Of Colorado | Gefitinib sensitivity-related gene expression and products and methods related thereto |
ES2315834T3 (es) * | 2004-02-03 | 2009-04-01 | Astrazeneca Ab | Derivados de quinazolina. |
AU2005249492B2 (en) * | 2004-05-27 | 2011-09-22 | The Regents Of The University Of Colorado | Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients |
JP2008501675A (ja) * | 2004-06-04 | 2008-01-24 | アストラゼネカ アクチボラグ | Erbb受容体型チロシンキナーゼとしてのキナゾリン誘導体 |
JP2008516973A (ja) | 2004-10-15 | 2008-05-22 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
ATE501148T1 (de) * | 2004-12-14 | 2011-03-15 | Astrazeneca Ab | Pyrazolopyrimidinverbindungen als antitumormittel |
GB0504474D0 (en) * | 2005-03-04 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
JP2008533053A (ja) * | 2005-03-11 | 2008-08-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド | ヒストン脱アセチル化酵素阻害剤は、がん細胞を上皮増殖因子受容体阻害剤に対して感受性にする |
GB0508715D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
GB0508717D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
WO2007023073A2 (de) * | 2005-08-22 | 2007-03-01 | Boehringer Ingelheim International Gmbh | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
JP2009508918A (ja) * | 2005-09-20 | 2009-03-05 | アストラゼネカ アクチボラグ | 癌治療のためのerbB受容体チロシンキナーゼ阻害剤としての4−(1H−インダゾール−5−イル]アミノ)キナゾリン化合物 |
US20090239861A1 (en) * | 2005-09-20 | 2009-09-24 | Robert Hugh Bradbury | Quinazoline derivatives as anticancer agents |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
EP1957499A1 (en) * | 2005-12-02 | 2008-08-20 | AstraZeneca AB | 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors |
WO2007063293A1 (en) * | 2005-12-02 | 2007-06-07 | Astrazeneca Ab | Quinazoleine derivatives used as inhibitors of erbb tyrosine kinase |
SG174774A1 (en) * | 2006-09-11 | 2011-10-28 | Curis Inc | Quinazoline based egfr inhibitors containing a zinc binding moiety |
US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
US20100120717A1 (en) | 2006-10-09 | 2010-05-13 | Brown Jason W | Kinase inhibitors |
BRPI0912170A2 (pt) | 2008-05-13 | 2015-10-13 | Astrazeneca Ab | composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente |
CN102452988B (zh) | 2010-10-27 | 2016-01-27 | 中国科学院化学研究所 | 一种喹唑啉衍生物及其制备方法 |
JP6026441B2 (ja) | 2011-03-04 | 2016-11-16 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | キナーゼ阻害剤としてのアミノキノリン |
TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
AR092530A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
TWI592417B (zh) * | 2012-09-13 | 2017-07-21 | 葛蘭素史克智慧財產發展有限公司 | 胺基喹唑啉激酶抑制劑之前藥 |
AR094707A1 (es) | 2013-02-21 | 2015-08-19 | Glaxosmithkline Ip Dev Ltd | Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2 |
BR112019010020A2 (pt) | 2016-11-17 | 2019-08-20 | Univ Texas | compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20 |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3812257A (en) * | 1972-04-07 | 1974-05-21 | Sumitomo Chemical Co | Uricosuric agent |
US3971783A (en) * | 1973-03-07 | 1976-07-27 | Pfizer Inc. | 4-Aminoquinazoline derivatives as cardiac stimulants |
US4335127A (en) * | 1979-01-08 | 1982-06-15 | Janssen Pharmaceutica, N.V. | Piperidinylalkyl quinazoline compounds, composition and method of use |
KR910006138B1 (ko) | 1986-09-30 | 1991-08-16 | 에자이 가부시끼가이샤 | 환상아민 유도체 |
US5411963A (en) | 1988-01-29 | 1995-05-02 | Dowelanco | Quinazoline derivatives |
US4921863A (en) * | 1988-02-17 | 1990-05-01 | Eisai Co., Ltd. | Cyclic amine derivatives |
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
US5409930A (en) | 1991-05-10 | 1995-04-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
AU2010792A (en) | 1991-05-20 | 1992-12-30 | Rhone-Poulenc Rorer International (Holdings) Inc. | Aromatic oligomeric compounds useful as mimics of bioactive macromolecules |
US5441963A (en) * | 1991-12-20 | 1995-08-15 | Merrell Dow Pharmaceuticals | Potentiation of NMDA antagonists |
GB9300059D0 (en) * | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
US5395846A (en) | 1993-06-25 | 1995-03-07 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Amino Bi- and tri-carbocyclic aklane bis-aryl squalene synthase inhibitors |
WO1995007267A1 (fr) | 1993-09-10 | 1995-03-16 | Eisai Co., Ltd. | Compose de quinazoline |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
GB2295387A (en) | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
EP0817775B1 (en) | 1995-03-30 | 2001-09-12 | Pfizer Inc. | Quinazoline derivatives |
GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
GB9508535D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
AU5343096A (en) | 1995-04-27 | 1996-11-18 | Zeneca Limited | Quinazoline derivatives |
GB9508537D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
GB9515975D0 (en) | 1995-08-04 | 1995-10-04 | Zeneca Ltd | Chemical compounds |
US6127366A (en) * | 1995-11-22 | 2000-10-03 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
GB9604311D0 (en) * | 1996-02-29 | 1996-05-01 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase |
WO1997018813A1 (en) | 1995-11-22 | 1997-05-29 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
US6313127B1 (en) * | 1996-02-02 | 2001-11-06 | Zeneca Limited | Heterocyclic compounds useful as pharmaceutical agents |
SK285141B6 (sk) | 1996-02-13 | 2006-07-07 | Astrazeneca Uk Limited | Použitie chinazolínového derivátu, chinazolínový derivát, spôsob jeho prípravy a farmaceutická kompozícia, ktorá ho obsahuje |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
GB9603097D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
KR100489174B1 (ko) | 1996-03-05 | 2005-09-30 | 제네카-파마 소시에떼아노님 | 4-아닐리노퀴나졸린유도체 |
DK0892789T4 (da) | 1996-04-12 | 2010-04-06 | Warner Lambert Co | Irreversible inhibitorer af tyrosin kinaser |
GB9607729D0 (en) | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
ID19609A (id) | 1996-07-13 | 1998-07-23 | Glaxo Group Ltd | Senyawa-senyawa heterosiklik |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
EP1014953B1 (en) | 1997-03-05 | 2012-04-25 | Sugen, Inc. | Formulations for hydrophobic pharmaceutical agents |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
DE19816983A1 (de) | 1998-04-17 | 1999-10-21 | Boehringer Ingelheim Pharma | Bicyclen, deren Herstellung und deren Verwendung als Arzneimittel |
US6200976B1 (en) * | 1998-04-17 | 2001-03-13 | Boehringer Ingelheim Pharma Kg | Antithrombotic quinoxazolines |
WO2000009481A1 (fr) | 1998-08-11 | 2000-02-24 | Takeda Chemical Industries, Ltd. | Composes d'amide cyclique, procedes de production correspondants, intermediaires correspondants et herbicides |
KR20010089171A (ko) | 1998-08-21 | 2001-09-29 | 추후제출 | 퀴나졸린 유도체 |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
US6297258B1 (en) * | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
EA003786B1 (ru) * | 1998-11-19 | 2003-10-30 | Варнер Ламберт Компани | N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ |
DE19908567A1 (de) | 1999-02-27 | 2000-08-31 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
JP3751201B2 (ja) * | 1999-02-27 | 2006-03-01 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | チロシンキナーゼにより媒介されるシグナル伝達に関する抑制効果を有する4−アミノ−キナゾリン誘導体及びキノリン誘導体 |
US6080747A (en) * | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
DE19911509A1 (de) * | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
YU13200A (sh) | 1999-03-31 | 2002-10-18 | Pfizer Products Inc. | Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja |
KR100709909B1 (ko) * | 1999-06-21 | 2007-04-24 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 비사이클릭 헤테로사이클, 이를 함유하는 의약 조성물 및 이의 제조방법 |
ATE398120T1 (de) * | 1999-11-05 | 2008-07-15 | Astrazeneca Ab | Neue quinazolin-derivate |
UA73993C2 (uk) * | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
DE10040527A1 (de) | 2000-08-18 | 2002-02-28 | Boehringer Ingelheim Pharma | Chinazoline und Verfahren zu ihrer Herstellung |
US6740651B2 (en) * | 2000-08-26 | 2004-05-25 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
US6653305B2 (en) * | 2000-08-26 | 2003-11-25 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
US6617329B2 (en) * | 2000-08-26 | 2003-09-09 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines and their use as medicaments |
US20020082270A1 (en) * | 2000-08-26 | 2002-06-27 | Frank Himmelsbach | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
US6656946B2 (en) * | 2000-08-26 | 2003-12-02 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
US20030158196A1 (en) * | 2002-02-16 | 2003-08-21 | Boehringer Ingelheim Pharma Gmbh Co. Kg | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors |
US7019012B2 (en) * | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
NZ516873A (en) | 2001-02-12 | 2003-11-28 | Warner Lambert Co | Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage |
CA2442742A1 (en) | 2001-02-21 | 2002-08-29 | Mitsubishi Pharma Corporation | Quinazoline derivatives |
US6562319B2 (en) * | 2001-03-12 | 2003-05-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy |
WO2002092578A1 (en) * | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | Quinazoline derivatives |
EP1396488A1 (en) * | 2001-05-23 | 2004-03-10 | Mitsubishi Pharma Corporation | Fused heterocyclic compound and medicinal use thereof |
GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
WO2003040108A1 (en) * | 2001-11-03 | 2003-05-15 | Astrazeneca Ab | Quinazoline derivatives as antitumor agents |
DE10204462A1 (de) * | 2002-02-05 | 2003-08-07 | Boehringer Ingelheim Pharma | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
TW200813014A (en) * | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
AU2003226705B2 (en) * | 2002-03-30 | 2008-11-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 4-(N-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors |
US6924285B2 (en) * | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
US20040044014A1 (en) * | 2002-04-19 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof |
US20030225079A1 (en) * | 2002-05-11 | 2003-12-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy |
US20050148607A1 (en) * | 2002-06-03 | 2005-07-07 | Tsuyoshi Suzuki | Preventives and/or remedies for subjects with the expression or activation of her2 and/or egfr |
AU2003257666A1 (en) | 2002-08-23 | 2004-03-11 | Kirin Beer Kabushiki Kaisha | COMPOUND HAVING TGFss INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME |
GB0309009D0 (en) * | 2003-04-22 | 2003-05-28 | Astrazeneca Ab | Quinazoline derivatives |
GB0309850D0 (en) * | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
GB0317665D0 (en) * | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
WO2005012290A1 (en) * | 2003-07-29 | 2005-02-10 | Astrazeneca Ab | Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors |
GB0321648D0 (en) * | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
EP1667996B1 (en) * | 2003-09-16 | 2009-07-22 | Astrazeneca AB | Quinazoline derivatives |
JP2007505873A (ja) * | 2003-09-16 | 2007-03-15 | アストラゼネカ アクチボラグ | チロシンキナーゼ阻害剤としてのキナゾリン誘導体 |
ES2281007T3 (es) * | 2003-09-19 | 2007-09-16 | Astrazeneca Ab | Derivados de quinazolina. |
MXPA06003341A (es) * | 2003-09-25 | 2006-06-08 | Astrazeneca Ab | Derivados de quinazolina. |
GB0322409D0 (en) * | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
GB0326459D0 (en) * | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
ES2315834T3 (es) * | 2004-02-03 | 2009-04-01 | Astrazeneca Ab | Derivados de quinazolina. |
EP1748387B1 (en) * | 2004-05-21 | 2018-12-05 | Asahi Kasei Kabushiki Kaisha | Devices for classifying the arousal state of the eyes of a driver, corresponding method and computer readable storage medium |
JP2008501675A (ja) * | 2004-06-04 | 2008-01-24 | アストラゼネカ アクチボラグ | Erbb受容体型チロシンキナーゼとしてのキナゾリン誘導体 |
-
2004
- 2004-09-13 DK DK04768469T patent/DK1667991T3/da active
- 2004-09-13 WO PCT/GB2004/003923 patent/WO2005026150A1/en active IP Right Grant
- 2004-09-13 SI SI200430769T patent/SI1667991T1/sl unknown
- 2004-09-13 BR BRPI0414489A patent/BRPI0414489A8/pt not_active Application Discontinuation
- 2004-09-13 JP JP2006526682A patent/JP4795952B2/ja not_active Expired - Fee Related
- 2004-09-13 PT PT04768469T patent/PT1667991E/pt unknown
- 2004-09-13 US US10/573,090 patent/US7569577B2/en not_active Expired - Fee Related
- 2004-09-13 AT AT04768469T patent/ATE395346T1/de not_active IP Right Cessation
- 2004-09-13 CA CA2538884A patent/CA2538884C/en not_active Expired - Fee Related
- 2004-09-13 PL PL04768469T patent/PL1667991T3/pl unknown
- 2004-09-13 UA UAA200604148A patent/UA84167C2/ru unknown
- 2004-09-13 ES ES04768469T patent/ES2305844T3/es active Active
- 2004-09-13 EP EP04768469A patent/EP1667991B1/en active Active
- 2004-09-13 AU AU2004272348A patent/AU2004272348B2/en not_active Ceased
- 2004-09-13 RU RU2006112599/04A patent/RU2378268C2/ru not_active IP Right Cessation
- 2004-09-13 MX MXPA06002964A patent/MXPA06002964A/es active IP Right Grant
- 2004-09-13 DE DE602004013806T patent/DE602004013806D1/de active Active
- 2004-09-14 TW TW093127785A patent/TW200519104A/zh unknown
- 2004-09-16 AR ARP040103321A patent/AR045663A1/es not_active Application Discontinuation
-
2006
- 2006-03-12 IL IL174261A patent/IL174261A0/en unknown
- 2006-03-23 NO NO20061322A patent/NO20061322L/no not_active Application Discontinuation
- 2006-04-10 CO CO06034940A patent/CO5690594A2/es not_active Application Discontinuation
- 2006-10-31 HK HK06111949A patent/HK1091480A1/xx not_active IP Right Cessation
-
2008
- 2008-07-07 HR HR20080329T patent/HRP20080329T3/xx unknown
- 2008-07-10 CY CY20081100724T patent/CY1108186T1/el unknown
-
2009
- 2009-06-11 US US12/482,620 patent/US20090312343A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2005026150A1 (en) | 2005-03-24 |
AU2004272348B2 (en) | 2008-09-04 |
RU2378268C2 (ru) | 2010-01-10 |
US20070043009A1 (en) | 2007-02-22 |
DK1667991T3 (da) | 2008-08-18 |
MXPA06002964A (es) | 2006-06-14 |
JP4795952B2 (ja) | 2011-10-19 |
PL1667991T3 (pl) | 2008-12-31 |
EP1667991B1 (en) | 2008-05-14 |
DE602004013806D1 (en) | 2008-06-26 |
BRPI0414489A8 (pt) | 2019-01-15 |
HRP20080329T3 (en) | 2008-08-31 |
AR045663A1 (es) | 2005-11-02 |
SI1667991T1 (sl) | 2008-10-31 |
RU2006112599A (ru) | 2007-11-10 |
US20090312343A1 (en) | 2009-12-17 |
ES2305844T3 (es) | 2008-11-01 |
TW200519104A (en) | 2005-06-16 |
UA84167C2 (ru) | 2008-09-25 |
CA2538884C (en) | 2010-09-21 |
HK1091480A1 (en) | 2007-01-19 |
CA2538884A1 (en) | 2005-03-24 |
CO5690594A2 (es) | 2006-10-31 |
AU2004272348A1 (en) | 2005-03-24 |
US7569577B2 (en) | 2009-08-04 |
PT1667991E (pt) | 2008-07-14 |
IL174261A0 (en) | 2006-08-01 |
JP2007505872A (ja) | 2007-03-15 |
ATE395346T1 (de) | 2008-05-15 |
EP1667991A1 (en) | 2006-06-14 |
CY1108186T1 (el) | 2014-02-12 |
BRPI0414489A (pt) | 2006-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20061322L (no) | Kinazolinderivater som tyrosin kinase inhibitorer | |
NO20061323L (no) | Kinazolinderivater | |
NO20061327L (no) | Kinazolinderivater | |
NO20061415L (no) | Kinazolinderivater | |
NO20061743L (no) | Kinazolinderivater | |
HK1087613A1 (en) | Quinazoline derivatives and their use in the treatment of cancer | |
RS20050363A (en) | Chk-,pdk-and akt-inhibitory pyrimidines,their production an use as pharmaceutical agents | |
CY1109681T1 (el) | Υποκατεστημενα παραγωγα κιναζολινης ως αναστολεις των κινασων aurora | |
NO20066081L (no) | Kinazolinderivater som erbB-reseptortyrosinkinaser | |
NO20070514L (no) | Pyrrolotriazin kinase inhibitorer | |
NO20064895L (no) | 6,6-Bisykliske ring-substituerte heterobisykliske protein-kinase inhibitorer | |
IS2855B (is) | 4-anilínókínasólínafleiður sem andfjölgunarefni | |
NO20092737L (no) | Substituerte pyrazolo-kinazolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som kinase-inhibitorer | |
NO20062763L (no) | Pyrrolotriazinforbindelser som kinaseinhibitorer | |
NO20081893L (no) | 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft | |
NO20080675L (no) | P38-Map kinaseinhibitorer og metoder for deres anvendelse | |
NO20081952L (no) | Substituerte pyrazolforbindelser | |
NO20073140L (no) | Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser | |
NO20085217L (no) | Effektive pyrimidinderivater i behandlingen av kreft | |
NO20065727L (no) | Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter | |
NO20071320L (no) | Pyrazolsubstituerte aminoheteroarylforbindelser som protein kinase inhibitorer. | |
NO20060415L (no) | Piperidyl-Kinazolinderivater som Tyrosin-Kinase-Inhibitorer | |
NO20072747L (no) | Fremgangsmate for fremstilling av indazolforbindelser | |
WO2008078100A3 (en) | Tricyclic amine derivatives as protein tyrosine kinase inhibitors | |
NO20023831L (no) | Pyrrol substituert 2-indolinonproteinkinaseinhibitorer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |